Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.50 |
| ▸ | JAK2 | O60674 | 6/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 6/20 | 0.40 |
| ▸ | CDK1 | P06493 | 2/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 3/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3304389 | 0.92 | EGLN2 (0.48) | ABCG2JAK2EGLN2KDRCDK1 | |
| SCHEMBL3308589 | 0.90 | EGLN2 (0.46) | ABCG2JAK2GRM4EGLN2KDR | |
| SCHEMBL3304524 | 0.83 | ABCG2 (0.49) | ABCG2JAK2EGLN2 | |
| SCHEMBL3308062 | 0.80 | JAK2 (0.46) | JAK2GSK3B | |
| SCHEMBL3301223 | 0.79 | KDR (0.52) | JAK2KDRCDK1 | |
| SCHEMBL3300917 | 0.79 | JAK2 (0.45) | JAK2KDRGSK3B | |
| SCHEMBL3303037 | 0.75 | EGLN2 (0.42) | JAK2EGLN2 | |
| SCHEMBL3303925 | 0.74 | JAK2 (0.48) | JAK2EGLN2 | |
| SCHEMBL3300212 | 0.74 | JAK2 (0.48) | JAK2EGLN2FLT3 | |
| SCHEMBL3304002 | 0.74 | JAK2 (0.45) | JAK2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | ABCG2 1632/4885JAK2 26/4885GRM4 2998/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | ABCG2 1632/4885JAK2 26/4885GRM4 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.